Related Experiment Video
Updated: Jan 8, 2026

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Sodium-Glucose Cotransporter-2 Inhibitors Following Transcatheter Aortic Valve Replacement: A Meta-Analysis
Hritvik Jain1, Kriti Soni2, Jyoti Jain3
1From the Department of Medicine, All India Institute of Medical Sciences, Jodhpur, India.
Abstract:
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce heart failure (HF)-associated admissions; however, the data on patients with aortic stenosis following transcatheter aortic valve replacement (TAVR) is limited. This systematic review and meta-analysis compares clinical outcomes in patients with and without SGLT2i following TAVR. Major electronic databases were systematically searched through April 2025 for studies evaluating SGLT2i following TAVR. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using a random-effects model. A P value of ≤0.05 was considered statistically significant. Two studies with 1534 patients undergoing TAVR (679: SGLT2i; 855: no SGLT2i) were included. SGLT2i therapy led to a significant reduction in HF hospitalization (RR: 0.56; 95% CI: 0.32-0.99; P = 0.05); however, no differences in all-cause (RR: 0.48; 95% CI: 0.13-1.72; P = 0.26) and cardiovascular mortality (RR: 0.53; 95% CI: 0.19-1.48; P = 0.22) were noted. SGLT2i are associated with a statistically and clinically significant reduction in HF hospitalization; however, no reduction in mortality was observed following TAVR. Further randomized controlled trials are warranted to support future guideline recommendations regarding SGLT2i following TAVR.
More Related Videos
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Secondary Active Transport